Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Clinical trial NCT05495035 · UNKNOWN

Trial details

NCT number: NCT05495035
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoblastic Leukemia, Acute, Childhood Leukemia, Lymphoblastic, Acute, Philadelphia-Positive Relapsed Leukemia Refractory Leukemia

Start date: 2022-09-01
Primary completion: 2024-08-31
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.